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Abstract
Despite the importance of microRNAs (miRs) for regulation of the delicate balance between cell proliferation and death,
evidence for their specific involvement during death receptor (DR)-mediated apoptosis is scarce. Transfection with miR-
133b rendered resistant HeLa cells sensitive to tumor necrosis factor-alpha (TNFa)-induced cell death. Similarly, miR-133b
caused exacerbated proapoptotic responses to TNF-related apoptosis-inducing ligand (TRAIL) or an activating antibody to
Fas/CD95. Comprehensive analysis, encompassing global RNA or protein expression profiling performed by microarray
experiments and pulsed stable isotope labeling with amino acids in cell culture (pSILAC), led to the discovery of the
antiapoptotic protein Fas apoptosis inhibitory molecule (FAIM) as immediate miR-133b target. Moreover, miR-133b
impaired the expression of the detoxifying protein glutathione-S-transferase pi (GSTP1). Expression of miR-133b in tumor
specimens of prostate cancer patients was significantly downregulated in 75% of the cases, when compared with matched
healthy tissue. Furthermore, introduction of synthetic miR-133b into an ex-vivo model of prostate cancer resulted in
impaired proliferation and cellular metabolic activity. PC3 cells were also sensitized to apoptotic stimuli after transfection
with miR-133b similar to HeLa cells. These data reveal the ability of a single miR to influence major apoptosis pathways,
suggesting an essential role for this molecule during cellular transformation, tumorigenesis and tissue homeostasis.
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Introduction
Apoptosis, a strictly regulated form of active programmed cell
death (PCD), plays crucial roles in a plethora of both homeostatic
and pathological processes in multicellular organisms [1].
Apoptotic cells are characterized by well-defined morphological
changes some of which include rounding-up of the cell, reduction
of cellular volume, chromatin condensation, nuclear fragmenta-
tion and membrane blebbing [2]. This process of controlled
cellular suicide can be triggered by extracellular and intracellular
stimuli, both of which result in activation of specific, yet partially
overlapping signaling cascades. Death receptors (DRs) represent
a group of extracellular membrane-bound molecules responsible
for sensing and transducing exogenously derived proapoptotic
signals. DRs, including tumor necrosis factor receptor 1 and 2
(TNFR1/2), Fas/CD95 and TNF-related apoptosis-inducing
ligand (TRAIL) receptors DR4 and DR5, belong to the TNF
superfamily and share a common structurally conserved 80 amino
acid-long cytoplasmic death domain (DD) [3]. Upon cognate
ligand binding, DRs oligomerize via their DD giving rise to
a scaffold for the recruitment of several adaptor and signaling
molecules. At this death-inducing signaling complex (DISC),
initiator caspases such as caspase 8 and 10 become activated by
autocatalytic cleavage. Once triggered, initiator caspases initiate
the execution phase of the death signal by processing effector
caspases, like caspase 3, 7 or 9, to their active forms. As
a consequence of this released proteolytic activity, caspase
substrates including key intracellular factors are degraded and
the cell is inevitably committed to death [4]. Cells harbor
a complex set of mechanisms aimed at regulating their re-
sponsiveness to DR ligands. For instance, cells can avoid initiation
of the proapoptotic program by survival factors that impair
caspase activation. The relevance of apoptosis and the proper
function of its negative regulators for systemic homeostasis are
exemplified by human patients suffering from devastating diseases
like cancer, neurodegeneration or autoimmunity.
MicroRNAs (miRs) are endogenous short (,22 nt) RNA
molecules that play an essential role in regulation of cellular
processes [5]. To date, the best characterized function of miRs is
fine tuning of gene activity at the post-transcriptional level. To this
end mature miRs are incorporated into an elaborate ribonucleo-
protein structure termed RNA-induced signaling complex (RISC).
Once RISC is loaded with an miR, it exploits its ‘seed sequence’ to
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35345find matching mRNAs. Depending on the degree of complemen-
tarity between the miR and its target, mRNA expression is blocked
either through direct cleavage or translational arrest [6]. Although
several miRs are capable of controlling pro- or antiapoptotic
processes, the role of miRs in regulation of DR-triggered apoptosis
remains elusive [7].
MiR-133b and -206 comprise a bi-cistronic miR cluster
originally suggested to be solely expressed in skeletal muscle [8].
Current studies support a broader expression pattern of this cluster
and attribute miR-206 important regulatory functions in tissues as
diverse as brain, skeletal muscle or adipose tissue [8,9,10].
Moreover, miR-206 activates apoptosis and inhibits tumor cell
migration and focus formation [11]. MiR-133b, the other cluster’s
member, is expressed in T-cells [12] and is downregulated during
head and neck/oral, bladder, human non-small cell lung,
colorectal and esophageal squamous cell cancer
[13,14,15,16,17,18,19,20]. MiR-133b targets important sentinels
of mitochondrial membrane integrity such as induced myeloid
leukemia cell differentiation protein (MCL-1) and BCL2-like 2
(BCL2L2) and the oncogenes Fascin homolog 1 (FSCN-1) and
tyrosine protein kinase c-Met (c-MET) [17,19,21]. More recently,
and diverging from the aforementioned findings a protumorigenic
role of miR-133b was found in cervical cancer [22]. Herein, we
characterized miR-133b in the context of DR-mediated apoptosis
and prostate cancer. We provide conclusive mechanistic evidence
for miR-133b as a regulator of proapoptotic signaling events that
apparently play an important role during cancerogenesis of the
human prostate.
Results
MiR-133b sensitizes cells to DR-mediated apoptosis
In order to assess whether miR-133b possesses proapoptotic
properties, we transfected HeLa cells with a synthetic miR-133b
mimic or a negative scrambled control (ctrl miR), stimulated them
with TNFa and characterized the cellular response by measuring
independent apoptosis markers. In HeLa cells, TNFa-induced
apoptosis can be blocked in a NF-kB-dependent manner [23].
Upon activation, NF-kB is released from its inhibitor, translocates
to the nucleus and induces expression of antiapoptotic molecules
[24]. After transfection with miR-133b, this antiapoptotic response
could be bypassed, rendering cells sensitive to TNFa-triggered
caspase 8 and 3 activation (Figure 1A). In line with this, poly [ADP
ribose] polymerase 1 (PARP-1) cleavage, a hallmark of apoptotic
cells [25], could only be detected in miR-133b transfectants
(Figure 1B). Both effects took place in a sequence-specific manner,
since transfection of ctrl miR did not result in altered activation
status of initiator and executer caspases or PARP-1 degradation.
Moreover, TNFa sensitization could be inhibited by adding
a specific miR-133b inhibitor (amiR-133b), but not a random
control sequence (ctrl amiR) [26,27]. Remarkably, activation
status of caspase 8 and 3 in unstimulated cells, as well as the
amount of cleaved PARP-1, were also significantly and specifically
Figure 1. miR-133b acts proapoptotically on HeLa cells stimulated with death receptor (DR) ligands. Cells were transfected with miR-
133b alone or together with a control antimiR (ctrl amiR) or a specific miR-133b inhibitor (amiR-133b). After 48 h, cells were either left untreated
(Unstim) or stimulated for 4 h with 20 ng/ml tumor necrosis factor-alpha (TNFa), 100 ng/ml of a cross-linking activating antiFas antibody (aFas/CD95)
or 20 ng/ml recombinant human TRAIL (rhTRAIL). (A) Treated cells were harvested, stained and scanned by flow cytometry for the presence of
cleaved active caspase 8 (upper graph) and 3 (lower graph). 7-Amino-actinomycin D (7-AAD) served for exclusion of cells with compromised
membrane integrity from the caspase activation quantification assay. Cells transfected with ctrl miR alone were used as reference. (B) Western blot
analysis of poly [ADP ribose] polymerase (PARP-1) in transfected, unstimulated cells (upper panel) and TNFa-, aFas/CD95- or rhTRAIL-treated cells
(lower panel). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal loading control. Graphs are representative of at least
three independent experiments. Asterisk represents p,0.01. Errors bars indicate standard deviation.
doi:10.1371/journal.pone.0035345.g001
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blocked in a sequence-specific manner by introduction of amiR-
133b (Figure 1A and B). We next inquired whether miR-133b
could also affect cellular responses to other DR ligand family
members. Comparable to TNFa resistance, Fas ligand (FasL)
refractory cells do not undergo apoptosis upon receptor ligation
[28]. MiR-133b transfection reversed this phenotype and induced
a 5-fold stronger activation of caspase 8 and 3, together with
PARP-1 depletion, after treatment of cells with a cross-linking
antiFas/CD95 (aFas/CD95) antibody. TRAIL-stimulated cells
exhibited a basal level of caspase activation and PARP cleavage,
which was potentiated following introduction of miR-133b. In
both cases, effects were sequence-specific and could be fully
reversed by cotransfection of fully complementary amiR, but not
by a negative control (Figure 1A and B).
Late apoptotic cells are characterized by compromised plasma
membrane integrity [29]. To test whether miR-133b insertion
leads to promiscuous rupture of the cellular envelope, transfected
cells were stimulated with different DR ligands and stained with
propidium iodide (PI). Whereas ctrl miR-treated cells hardly
stained positive for PI after TNFa or aFas/CD95 treatment, miR-
133b led to a marked increase of the PI-positive population under
the same conditions. Loss of plasma membrane integrity was also
much stronger in TRAIL-treated miR-133b-transfected cells
(Figure 2). Importantly, and verifying the proapoptotic nature of
miR-133b, pre-treatment with a cell permeable nonselective
caspase inhibitor (Z-VAD-FMK) almost completely rescued
cellular resistance to DR stimulation (Figure 2).
Fas apoptosis inhibitory molecule (FAIM) is directly
regulated by miR-133b
Next, we questioned which genes are directly targeted by miR-
133b. Whole genome microarray expression analysis allowed us to
record mRNAs with impaired expression after miR-133b trans-
fection (Microarray data have been deposited in GEO GSE24613.
The data are MIAMI compliant and are available through the
following link: http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token=jnadregqswauixm&acc=GSE24613). Assuming that
miR-133b primarily acts by restraining induction of canonical
antiapoptotic factors, cells were stimulated with TNFa for 6 h
prior to RNA collection. Under these conditions a total of 305
genes (for a detailed gene list please refer to deposited microarray
files) emerged as downregulated (FCH,21.5; p-value,0.001).
We also obtained 409 induced genes, but as miRNAs are, in
general, supposed to repress gene expression, we focused on
downregulated genes in our further analysis. Consistent with
published results, the observed mRNA changes were not drastic
and peaked at a minimum of 24.8 fold [30]. In order to filter the
data for genes with the necessary sequence features to be
considered as potential miR-133b targets, we matched the list of
downregulated genes with miRecords, an miR target prediction
database (Table 1). This online accessible repository is an archive
of results produced by 11 established miR target prediction
programs [31]. Given the proapoptotic nature of miR-133b, the
antiapoptotic gene Fas apoptosis inhibitory molecule (FAIM)
captured our attention as an interesting miR-target candidate.
FAIM is a widely expressed and evolutionarily conserved
protein originally cloned from B cells and with protective traits
against Fas/CD95-mediated apoptosis [32]. The 39-UTR region
of FAIM contains one single miR-133b binding site (Figure 3A).
Cloning of complete 39-UTR of FAIM into psiCHECK-2
luciferase reporter plasmid reduced Renilla luciferase activity to
19% after cotransfection of miR-133b. Interaction between the
binding-site in the 39-UTR and miR-133b was sequence-specific,
since mutation of the seed sequence restored Renilla luciferase
activity (Figure 3B) to values comparable to the empty psiCHECK
vector. Moreover, as predicted by microarray analysis, miR-133b
transfection of HeLa cells translated into specific downregulation
of FAIM protein as demonstrated by Western blot analysis
(Figure 3C). On the mRNA level quantitative PCR (qPCR) also
revealed reduced amounts of FAIM molecules relative to human
acidic ribosomal protein (HuPO) as a house keeping gene
(Figure 3D).
MiR-133b impairs expression of glutathione-S-transferase
pi (GSTP1)
Microarray analysis of miR-mediated gene regulation relies
exclusively on mRNA decay. Since miR-mediated gene expression
repression also occurs at the translational level, we decided to
perform pulsed stable isotope labeling with amino acids in cell
culture (pSILAC) analysis of HeLa cells transfected with miR-133b
or control miR [33]. As done previously, transfected cells were
stimulated with TNFa for 6 h prior to protein lysate harvest. In
accordance with previous reports about quantitative effects of miR
activity on the cellular proteome, ectopic introduction of miR-
133b into HeLa cells led only to mild effects on overall protein
biosynthesis [33]. Among the most strongly repressed proteins,
glutathione-S-transferase pi (GSTP1) constituted an interesting
target gene, since it represents an important factor fulfilling
Figure 2. Transfection of HeLa cells with miR-133b results in
enhanced caspase-dependent loss of membrane integrity after
DR ligation. Cells were transfected with miR-133b alone or together
with ctrl miR. After 48 h, cells were left untreated (Unstim) or stimulated
for 4 h with either 20 ng/ml TNFa, 100 ng/ml aFas/CD95 or 20 ng/ml
rhTRAIL. In order to assess caspase dependency, 0.01% DMSO (vehicle)
(left histogram column) or Z-VAD-FMK (50 mM) (right histogram
column) were added to the cells. Following stimulation, both adherent
and suspension cells were collected, stained with propidium iodide (PI)
and analyzed by flow cytometry. Samples were compared to equally
treated ctrl miR-transfected cells (black histogram). Results are
representative of at least three independent experiments.
doi:10.1371/journal.pone.0035345.g002
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with this, cross-comparison of pSILAC results with microarray
expression analysis revealed repression of GSTP1 at the mRNA
level (Table 2). This had not been identified previously, because of
the filtering strategy applied to the miR-133b target predictions
according to miRecords (i.e. target prediction by at least three
independent tools; see Table 1). According to the in-silico
prediction tools TargetScan and MicroCosm Targets, GSTP1
displays one single miR-133b binding site in its 39-UTR
(Figure 4A) [35,36,37]. As demonstrated by luciferase reporter
assays, coupling of entire GSTP1 39-UTR to Renilla luciferase
specifically rendered it less active after cotransfection of miR-133b.
Supporting a direct interaction between miR-133b and the cloned
target sequence, mutation of the predicted seed sequence
reinstated enzymatic activity (Figure 4B). Moreover, qPCR
analysis corroborated the suppressive effect of miR-133b on the
mRNA levels of GSTP1 (Figure 4D). As the final line of evidence,
Western blot analysis confirmed the pSILAC results by proving
protein levels of GSTP1 to be miR-133b sensitive (Figure 4C) in
HeLA cells. Using pSILAC FAIM was not identified.
MiR-133b is downregulated in prostatic tissue from
cancer patients and induces proliferation arrest in PC3
cells
Previous studies described the downregulation of miR-133b in
cancer and discussed the potential of such miR signatures for
diagnosis and prognosis [13,14,15,16,17,18,19,21,38]. To prove
the biological significance of miR-133b dysregulation in cancer,
we examined miR-133b expression in 69 human prostate cancer
samples and matched normal adjacent tissue. Although normal-
ized ct-values varied in individual patients, mean miR-133b
expression was 1.7-fold decreased in tumor tissue (Wilcoxon signed
rank test; p,0.01), with 75% of examined patients displaying
lower expression (Figure 5). We did not observe a significant
correlation with Gleason Score (rs=20.20; p=0.10) or patholog-
ical stage (rs=20.16; p=0.18). ROC analysis and univariate
logistic regression revealed robust discrimination between tumor
and normal tissue by miR-133b with an area under the curve
(AUC) of 0.73 (p,0.001) and an overall correct classification of
68% (HR=0.94; 95% CI=0.91–0.98; p,0.01) (Figure S1). To
estimate whether patients with lower miR-133b expression have
a higher recurrence incidence, we dichotomized patients accord-
ing to median expression ratio in tumor tissue (T) versus normal
adjacent tissue (N) (Figure S2). Patients with a low T/N ratio had
significantly worse recurrence-free survival than patients with high
T/N ratio (log rank test; p,0.05). Univariate Cox regression of
continuous miR-133b ratio showed borderline significance of
miR-133b as predictive marker for biochemical relapse
(HR=0.16; 95% CI=0.02–1.06; p=0.06).
Having proven miR-133b dysregulation in prostate cancer
specimens, we addressed the question, whether reduced expression
levels of proapoptotic miR-133b could be a mechanism that allows
prostate cancer cells to circumvent cell death resulting in higher
proliferation rate. Therefore, we monitored ex-vivo the metabolic
activity of transfected PC3 cells for 6 days. Two days after
transfection, minor growth reduction could be observed in all
groups, which might have been due to slight cytotoxicity triggered
by the transient transfection procedure used. Afterwards, ctrl miR-
transfected cells resumed normal proliferation, while growth of
cells simultaneously treated with miR-133b and ctrl miR remained
repressed. Cotransfection of miR-133b and amiR-133b partially
abolished this inhibition, suggesting a sequence-specific effect
(Figure 6A). MiR-133b-mediated growth inhibition was relieved
after 96 h most likely due to the transient transfection protocol
used in this study. Indeed, also in apoptosis-inducing experiments
shown above, the proapoptotic effect catalyzed by miR-133b was
strongly reduced or even lost 96 h post-transfection (data not
shown). Similarly to the experiments performed in HeLa cells; we
then determined whether FAIM and GSTP1 represent miR-133b
target genes in prostate cancer cells. To this end, we transfected
the wildtype and binding site mutated reporter constructs in PC3
cells. As depicted in Figure 6B and C, luciferase activity was only
reduced if reporter vectors harboring the wildtype 39-UTR were
applied. This regulation was not only confined to the reporter
constructs but extends to the native proteins as revealed by
Western blots with GSTP1- or FAIM-specific antibodies (Figure
S3 and Figure S4). Next we examined if miR-133b is also involved
in DR-mediated apoptosis in prostate cancer cells. PC3 cells were
treated with DR ligands and active caspase levels were determined
(Figure 7). Following treatment with a combination of miR-133b
and TRAIL or aFas/CD95 antibodies, cellular apoptosis in-
creased as compared to ctrl miR, although this effect was less
pronounced than in HeLa cells. In contrast to HeLa cells,
stimulation with TNFa did not result in substantial apoptosis
under the experimental conditions. This could be attributed to the
chosen TNFa concentration and incubation times, which were
optimized for HeLa cells and lower than the ones used for PC3
cells in other reports [39]. We conclude that miR-133b functions
as a proapoptotic molecule in PC3 and HeLa cells. Recently,
a cancer-promoting role through activation of the ERK and
AKT1 pathways has been described for miR-133b in other
cervical cancer models [22]. To determine whether these signaling
pathways are activated in HeLA or PC3 cells we performed
Western blot analysis of miR-133b-transfected cells (Figure S5). In
contrast to other cervical cell lines, miR-133b expression did not
influence AKT1 or ERK phosphorylation in HeLa cells. As
a caveat we should note that ERK phosphorylation was barely
Table 1. Genes downregulated after transfection of HeLa
cells with miR-133b and TNFa stimulation and predicted to be
potential miR targets.
1
Symbol MiRanda MiRtarget2 Pita
Target
scan
FCH
array p-value
ACAT2 YES YES YES 21.6 8E-08
MYH9 YES YES YES 21.6 7E-07
SLC30A7 YES YES YES 21.6 3E-09
CPNE3 YES YES YES 21.7 3E-21
ARL13B YES YES YES 21.7 9E-21
FOXP4 YES YES YES 21.7 6E-08
ARL14 YES YES YES 21.7 8E-09
COQ7 YES YES YES 21.7 9E-13
TOR1AIP2 YES YES YES 21.8 5E-22
EFEMP1 YES YES YES 21.8 1E-24
SLC2A12 YES YES YES 21.9 7E-09
CETN3 YES YES YES 21.9 3E-11
FAIM YES YES YES YES 22.0 3E-20
CREB5 YES YES YES 22.3 8E-11
CTH YES YES YES 22.5 2E-33
KLRK1 YES YES YES 23.4 3E-37
1According to the online database miRecords and predicted at least by three
different algorithms.
doi:10.1371/journal.pone.0035345.t001
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to an ambivalent function of miR-133b, which can be pro- or
antiapoptotic depending on cell type.
Discussion
Herein, we used human cervix and prostate carcinoma cells as
a model system for DR-triggered apoptosis to interrogate whether
miR-133b is capable of modifying the cellular death response to
TNFa, Fas/CD95 ligand (FasL) or TRAIL. Our findings reveal
that miR-133b is a potent catalyzer of DR-mediated cell death.
The accentuated apoptotic response of miR-133b transfectants is
a direct consequence of synergistic alterations of their protein
repertoire. Specifically, miR-133b directly impairs the expression
of important antiapoptotic genes. We provide evidence for FAIM
as a target of miR-133b. Originally discovered during a screen
aiming to identify factors responsible for Fas/CD95 resistance in
primary splenic B cells, FAIM has emerged as a highly conserved
atypical regulator of DR-mediated apoptosis [32]. Since FAIM
does not exhibit a significant primary sequence homology to any
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Figure 3. Fas apoptosis inhibitory molecule (FAIM) expression is regulated by miR-133b. (A) miR-133b target sites within the 39-UTR of
FAIM as predicted by TargetScan and MicroCosm Targets. (B) 39-UTR targeting assay. HeLa cells were cotransfected with different combinations of
miR mimics and a luciferase reporter plasmid harboring the complete 39-UTR of FAIM (psiCHECK2-FAIM) or the mutated version thereof (psiCHECK2-
FAIM-mut). Template plasmid (psiCHECK2) was used as a negative and normalization control. Activity of the 39-UTR-dependent luciferase (Renilla
reniformis) was measured 48 h post-transfection and normalized for transfection efficiency to the one produced by the miR- and 39-UTR-independent
luciferase (Photinus pyralis). Error bars indicate standard deviation. (C) Western blot and densitometric analysis of FAIM expression. Cells were
transfected with miR-133b alone or together with ctrl amiR or specific amiR-133b. After 48 h, cellular protein lysates were prepared and FAIM
expression was assessed by Western blot. GAPDH was used as an internal loading standard. Ctrl miR-transfected cells were used as a reference for
densitometric quantification of protein band intensity. (D) qPCR analysis. Cells were transfected for 48 h before total RNA was isolated, reverse
transcribed and analyzed by qPCR for expression of FAIM. Human acidic ribosomal protein (HuPO) was used as the housekeeping gene for internal
normalization. Fold-change (FCH) values are shown relative to mock-transfected cells incubated under the same conditions. All graphs are
representative of at least three independent experiments.
doi:10.1371/journal.pone.0035345.g003
Table 2. Apoptosis regulatory proteins downregulated in miR-133b-transfected TNFa-stimulated HeLa cells.
UniProt name
1Fold repression Positive correlation with microarray analysis
2Predicted miR-133b targets
TAGLN2 4.2 YES YES
MYH9 2.7 YES YES
CKAP4 2.3 YES YES
PTBP1 2.2 YES YES
GSTP1 2.1 YES YES
CPNE3 1.9 YES YES
1Compared to ctrl miR-transfected and TNFa-stimulated cells. P-value,0.01.
2As predicted by either TargetScan or MicroCosm Targets.
doi:10.1371/journal.pone.0035345.t002
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reveal any insights on how it can exert its antiapoptotic function.
At present, two major isoforms of FAIM have been described.
The long isoform (FAIM-L) is present almost exclusively in
neurons, whereas the short one (FAIM-S) displays a much broader
expression pattern [40]. Over-expression studies in neurons
revealed a protective role of FAIM-L against TNFa- and FasL-
mediated apoptosis upstream of both caspase 8 and 3, and the
ability of FAIM-S to promote neurite outgrowth by a mechanism
involving activation of NF-kB [40,41]. Noticeably, FAIM-L and -S
share the same 39-UTR and miR-133b binding site, implying that
both are subjected to post-transcriptional regulation by miR-133b.
In fact, enriched presence of miR-133b was identified in the
midbrain region, where it regulates the maturation and function of
dopaminergic neurons [42]. Based on this observation and the
data provided here, it would be attractive to investigate the
interplay between FAIM and miR-133b during DR-triggered
apoptosis and neuron development in the midbrain.
Importantly, FAIM positively influences the expression of
central antiapoptotic cellular FLICE-like inhibitory protein
(cFLIP) in lymphocytes and hepatocytes in-vivo. Reduced levels
of cFLIP would allow a better physical interaction of procaspase 8
with Fas/CD95 thus leading to more pronounced caspase
activation and probably enhanced apoptosis [43]. To test whether
this was also the case in miR-133b-transfected cells, cFLIP
expression was analyzed. No significant difference of cFLIP
between ctrl miR- and miR-133b-transfected cells could be
observed at the mRNA or protein level (data not shown). A
possible explanation for this could be that generation of a knockout
mouse leads to complete absence of the deleted gene, whereas
transient miR treatment merely results in a partial reduction
(,70%) of protein expression. Therefore, miR-133b-transfected
cells might still contain sufficient FAIM to assure expression of
cFLIP. As the first reported post-transcriptional regulator of FAIM
and considering the high degree of conservation of miR-133b and
FAIM across different species, the role of miR-133b during further
biological processes should be a matter of future studies.
In addition to FAIM, we could further pinpoint the expression
of an important antiapoptotic enzyme as miR-133b-dependent by
using global proteome quantification techniques. GSTP1 belongs
to a family of enzymes responsible for detoxification and
protection of cells from attack by reactive species. GSTP1
expression is highly elevated in many neoplastic tissues and has
been implicated in resistance to apoptosis [34]. GSTP1 was
reported to regulate TNFa-triggered signaling through interaction
with TNF receptor-associated factor 2 (TRAF2). As a consequence
of this interaction, activation of apoptosis signal-regulating kinase
1 (ASK1) is impaired, and TNFa-mediated apoptosis is strongly
disturbed [44]. Recently, miR-133a, a cognate molecule of miR-
133b, was reported to regulate the expression of GSTP1 in head
and neck squamous cell carcinoma (HNSCC) cells [45]. MiR-133a
and b differ only in one base pair at the 39- end of the molecules
(GRA). This position is furthest away from the seed region, which
is essential for miR:target interaction. Hence, it is likely that
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Figure 4. miR-133b controls expression of glutathione-S-transferase pi (GSTP1). (A) miR-133b target sites within the 39-UTR of GSTP1 as
predicted by TargetScan and MicroCosm Targets. (B) 39-UTR targeting assay. HeLa cells were cotransfected with different combinations of miR mimics
and a luciferase reporter plasmid harboring the complete 39-UTR of GSTP1 (psiCHECK2-GSTP1) or the 39-UTR missing the miR-133b binding site
(psiCHECK2-GSTP1-mut). Template plasmid (psiCHECK2) was used as a negative and normalization control. Activity of the 39-UTR-dependent
luciferase (Renilla reniformis) was measured 48 h post-transfection and normalized for transfection efficiency to the one produced by the miR- and 39-
UTR-independent luciferase (Photinus pyralis). Error bars indicate standard deviation. (C) Western blot and densitometric analysis of GSTP1 expression.
Cells were transfected with miR-133b alone or together with ctrl amiR or a specific amiR-133b. After 48 h, cellular protein lysates were prepared and
GSTP1 expression was assessed by Western blot. GAPDH was used as an internal loading standard. Ctrl miR-transfected cells were used as a reference
for densitometric quantification of protein band intensity. (D) qPCR analysis. Cells were transfected for 48 h before total RNA was isolated, reverse
transcribed and analyzed by qPCR for the expression of GSTP1. HuPO was used as the housekeeping gene for internal normalization. Fold-change
(FCH) values are shown relative to mock-transfected cells incubated under the same conditions. All graphs are representative of at least three
independent experiments.
doi:10.1371/journal.pone.0035345.g004
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by regulating the expression of a common pool of target genes. In
addition, miR-133a and the co-transcribed miR-1 were recently
described to exhibit a reduced expression in prostate and bladder
cancer in which miR-133a targets Transgelin 2 (TAGLN2), a gene
with oncogenic properties that was strongly downregulated in our
pSILAC dataset [46,47,48].
So far, miR-133b has been almost exclusively described in the
context of miR signatures from tumor samples or cancer cell lines
and its potential for diagnostics and prognosis. Previous reports
demonstrate a significant downregulation of miR-133b in
transformed tissue compared to healthy controls
[13,14,16,18,21,38]. One recent report ascribes tumor-promoting
functions to miR-133b in in-vitro and in-vivo models of cervical
cancers [22]. This work focused on cervical cell lines other than
HeLa cells, which were inspected for their expression levels of
miR-133b. In this cell line miR-133b levels werefound to be
slightly elevated compared to other cervical cancer cell lines. Our
HeLa experiments point to a proapoptotic and presumably
antitumorigenic role of miR-133b. Therefore it is conceivable
that miR-133b fulfills different roles in HeLa cells and other
cervical cancer cell lines. It is well known that the same molecule
can have opposing roles in different cellular settings [49,50]. Note,
that differential results were obtained while examining the
expression of miR-133b in cervical cancer compared to healthy
tissue. One study reports upregulation of this miR as revealed by
qRT-PCR whereas a sequencing approach and microarray
analysis point to a repression of miR-133b in tumor tissue
[22,51,52]. Further experiments will be necessary to clarify this
conundrum of pro- or antiapoptotic functions of miR-133b in
cervical and other types of cancer.
Herein, we addressed the question whether miR-133b is also
downregulated in prostate cancer. We show that miR-133b
expression is reduced in the majority of prostate cancers when
compared to normal adjacent tissue. Remarkably, patients with
a low abundance of miR-133b tend to experience biochemical
relapse more frequently. Accordingly, transfection of a prostate
tumor cell line with synthetic miR-133b mimics resulted in
sequence-specific impairment of proliferation capacity, suggesting
a functional relevance of the reduced miR-133b expression in
cancerous prostate cells. Ongoing work focuses on elucidating the
exact molecular mechanisms responsible for this phenotype.
Finally, our results identify miR-133b as a highly versatile and
potent proapoptotic molecule with tumor suppressor properties.
The evidence provided here, in combination with previous
findings showing that miR-133b is concordantly repressed in
various tumor types and, that it is capable of regulating the
intrinsic apoptotic pathway and expression of important onco-
Figure 5. Samples from human prostate cancer patients have
decreased expression of miR-133b. Scatter dot-plot of miR-133b
expression. RT-qPCR was used to determine miR-133b expression in 69
primary prostate cancer tissues and corresponding normal adjacent
tissue. Lines represent mean expression values. MiR-133b was
normalized to miR-130b, since it shows a very stable expression
pattern both in tumors and normal tissue.
doi:10.1371/journal.pone.0035345.g005
Figure 6. Prostate cancer cells treated with miR-133b show impaired vitality. (A) MTT proliferation assay. PC3 cells were transfected with
ctrl miR (N) or, miR-133b together with ctrl amiR (&) or with a specific amiR-133b (m). Cellular viability and proliferation were determined 0, 48, 96
and 144 h post-transfection as described in Material and Methods. (B) 39-UTR targeting reporter assay. PC3 cells were transfected with miR mimics
and a luciferase reporter plasmid encompassing the complete 39-UTR of FAIM (psiCHECK2-FAIM) or the 39-UTR missing the miR-133b binding site
(psiCHECK2-FAIM-mut). The empty psiCHECK2 vector was used as a negative control. Error bars indicate standard deviation. (C) Congruent to (B)
except that luciferase assays were performed with a construct harboring the GSTP1 39-UTR.
doi:10.1371/journal.pone.0035345.g006
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represents an important step during tissue transformation [38].
Hence, further studies should aim at exploring the potential of
miR-133b as molecular target for cancer therapy.
Materials and Methods
Ethics statement
The study was approved by the ethical board of the Charite ´
University Hospital (EA1/153/07) and written informed consent
has been obtained.
Cell lines
HeLa and PC3 cells were obtained from the German Collection
of Microorganisms and Cell Cultures (DSMZ) (Braunschweig,
Germany). All cell lines were kept in culture under conditions
recommended by the American Type Culture Collection (ATCC)
(Manassas, VA, USA).
Patients and tissue samples
Tumor tissue and normal adjacent tissue from 69 patients with
prostate carcinoma were collected after radical prostatectomy at
Charite ´ University Hospital between 2001 and 2005. Samples
were snap-frozen directly after surgery. Tumor areas were
identified by haematoxylin and eosin staining and tumor and
normal adjacent tissue was punch-biopsied with a 1-mm tissue
microarray needle. Tumor content of the punches was histolog-
ically reevaluated to confirm a tumor content .90% in each
sample. Frozen matched malignant and nonmalignant samples
were collected in RNAlater stabilization reagent (Qiagen GmbH,
Hilden, Germany). For all patients, the following clinicopatholog-
ical information was available: Tumor classification according to
the International Union Against Cancer (UICC) 2002 TNM
system, tumor grading according to Gleason, follow-up time after
surgery and follow-up prostate-specific antigen (PSA) values.
Biochemical relapse was defined as the first PSA value after
radical prostatectomy .0.1 and was confirmed by a subsequently
elevated value. Additionally, only patients whose PSA levels
dropped below detection limit after surgery were considered for
analysis.
Reagents, cytokines and death receptor ligands
For stimulation and apoptosis induction experiments recombi-
nant human TNFa from Active Bioscience (Hamburg, Germany)
was used; human activating antiFas/CD95 (Clone CH11) (aFas/
CD95) was from Upstate (Temecula, CA, USA); soluble human
recombinant TRAIL was purchased from Alexis Biochemicals
(Farmingdale, NY, USA). For apoptosis inhibition the general
caspase inhibitor z-Val-Ala-DL-Asp(Ome)-fluoromethylketone (Z-
VAD-FMK) from BD-Biosciences (San Jose, CA, USA) was used.
miR mimics and inhibitor molecules
For transfection experiments synthetic miR-133b (Catalog
number PM10029), antimiR-133b (amiR-133b; catalog number
PM10029) and their respective scrambled controls: control miR
(ctrl miR; catalog number AM17110) and control antimiR (ctrl
amiR; catalog number AM17010) were purchased from Ambion
(Austin, TX, USA). Unless otherwise specified, negative control
and miRs were used at 10-nM concentration. For inhibition
experiments amiRs or scrambled control were added at 30-nM
concentration. All transfections were carried out using Lipofecta-
mine 2000 from Invitrogen (Carlsbad, CA, USA) according to the
manufacturer’s protocol.
Apoptosis assays
The day before transfection, HeLa or PC3 cells were seeded in
24-well plates at a density of 5610
4 cells/well. MiR-133b or ctrl
miR was transfected either alone or together with ctrl or specific
amiR-133b. Forty-eight h after transfection, cells were stimulated
for 6 h with the respective proapoptotic stimuli. Apoptotic cells
were quantified by flow cytometry by measuring caspase activation
status with caspase-specific FLICA
TM apoptosis detection kits from
Immunochemistry Technologies (Bloomington, MN, USA) as per
manufacturer’s instructions. 7-Amino-actinomycin D (7-AAD) was
used to exclude cells with damaged cellular membrane from the
caspase activation quantification. Propidium iodide (PI) incorpo-
ration was used for determining overall cell vitality. For this,
Figure 7. miR-133b induces increased apoptosis in DR receptor
stimulated PC3 cells. Cells were transfected with miR-133b (red) or
a control miR (ctrl miR, black), as reference. After 48 h, cells were either
left untreated (Unstim) or stimulated for 4 h with 20 ng/ml tumor
necrosis factor-alpha (TNFa), 100 ng/ml of a cross-linking activating
antiFas antibody (aFas/CD95) or 20 ng/ml recombinant human TRAIL
(rhTRAIL). Treated cells were harvested, stained and scanned by flow
cytometry for the presence of cleaved active caspase 8 (left) and
caspase 3 (right). 7-Amino-actinomycin D (7-AAD) was used for
exclusion of cells with compromised membrane integrity from the
caspase activation quantification assay.
doi:10.1371/journal.pone.0035345.g007
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gies) and analyzed by flow cytometry.
3-(4,5-Dimethylthiazol-2-yl)-2,5 diphenyltetrazolium
bromide (MTT) cell survival and proliferation assay
MTT was diluted in PBS to a final concentration of 5 mg/ml
and sterile filtered. Before use, MTT stock solution was further
diluted with cell culture medium (without FCS) to a final
concentration of 100 mg/ml. To perform the assay, 50 ml of this
solution were added to the culture plate containing transfected
cells in 50 ml supernatant. Treated cells were incubated for
another 5 h at 37uC and controlled hourly by light microscopy for
formation and precipitation of violet formazan crystals. Next, cell
culture supernatants were removed carefully, without disturbing
the cell monolayer. Adherent cells were lysed with 100 ml 100%
DMSO. Finally, DMSO samples containing diluted formazan
crystals were transferred to ELISA plates and OD570 values were
determined using a Spectramax 190 reader from Molecular
Devices (Sunnyvale, CA, USA).
Western blotting
For protein detection, PC3 or HeLa cells were transfected and
incubated for 48 h. Protein lysates were generated by collecting
and pooling the supernatants and adherent cells and washing them
briefly with phosphate-buffered saline. Cell pellets were lysed by
adding 16Laemmli sample buffer containing 62.5 mM Tris-HCl,
pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue and 2-
mercaptoethanol. Protein expression was analyzed by standard
procedures for Western blotting. A list of antibodies used in this
study can be found in Table S1. Proteins of interest were
normalized to GAPDH and analyzed densitometrically using
LAS-3000 CCD imaging system from Fujifilm (Tokyo, Japan) and
AIDA Biopackage-2D (Raytest, Straubenhardt, Germany).
RNA isolation and quantitative PCR
Total RNA for quantitative PCR was isolated with TRIzol from
Invitrogen according to total RNA-isolation protocol recom-
mended by the manufacturer and using glycogen (Ambion) as
a carrier. Quantitative PCR of miR-133b and miR-130 was
performed with TaqMan microRNA assays from Applied
Biosystems using 100 ng total RNA for the reverse transcription
step. For analysis of the protein-coding gene expression, 2 mg
RNA were reverse transcribed using random hexamers (Fermen-
tas, Burlington, Canada) and SuperScript III First-Strand
Synthesis System for RT-PCR (Invitrogen). After reverse tran-
scription all samples were subjected to DNAseI (Invitrogen)
treatment in order to remove contaminating genomic DNA. All
samples were analyzed with a 7900HT fast real-time PCR system
(Applied Biosystems) and subjected to comparative DDCt method
by using human acidic ribosomal protein (HuPO) as the internal
standard. For further information about all primers see Table S2.
RNA isolation and quantitative PCR from primary
prostate cancer tissue
Total RNA was extracted with the miRNeasy Mini Kit (Qiagen)
according to manufacturer’s recommendations. Quality and yield
was monitored using a NanoDrop ND-100 photometer (Thermo
Fisher Scientific Inc., Waltham, MA, USA) and a 2100 Bioana-
lyzer (Agilent Technologies, Santa Clara, CA, USA). Only samples
with RNA Integrity Numbers (RIN) above 6 were used for
subsequent analysis. Relative expression of miR-133b in prostate
tissue was measured as previously described [53]. cDNA was
reverse transcribed from 6.7 ng total RNA. Expression of miR-
133b was normalized to miR-130b [53]. Standard curves were
generated for each miRNA to allow for suboptimal efficiencies and
to calculate arbitrary concentrations.
Microarray analysis
Microarray experiments were performed as dual-color hybridi-
zations. To compensate for dye-specific effects, a dye-reversal
color-swap was applied. RNA labeling was performed with the
Quick Amp Labeling Kit (Agilent Technologies). In brief, mRNA
was reverse transcribed and amplified using an oligo-dT-T7-
promotor primer and resulting cRNA was labeled with dyes.
1.25 mg of each labeled cRNA was fragmented and subsequently
hybridized to whole human genome 44 k microarrays (AMADID-
014850) according to the supplier’s protocol (Agilent Technolo-
gies). Data files were further analyzed with the Rosetta Resolver
Biosoftware, Build 7.2 (Rosetta Biosoftware, Seattle, WA, USA). A
1.5-fold change expression cut-off for ratio experiments was
applied together with anticorrelation of ratio profiles rendering the
microarray analysis highly significant (P-value.0.01), robust and
reproducible. The data presented in this publication have been
deposited in NCBI’s Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession number GSE24613.
Pulsed stable isotope labeling with amino acids in cell
culture (pSILAC)
Changes in the proteome of miR-transfected HeLa cells were
analyzed by performing a slightly modified version of the pSILAC
method described by Selbach et. Al [33]. Briefly, 1.5610
6 HeLa
cells cultivated in normal light medium were transfected for 5 h
with ctrl miR or miR-133b. Treated cells were next transferred to
culture medium containing medium-heavy (M;
13C6-arginine and
2H4-lysine) or heavy (H;
13C6
15N4-arginine and
13C6
15N2-lysine)
isotope-labeled amino acids and pulse labeled for another 40 h. All
media were prepared using SILAC
TM D-MEM and amino acids
from Invitrogen and Thermo Fisher Scientific (Perbio Science).
Finally, both groups of cells were stimulated in the same media for
6 h with 25 ng/ml TNFa and processed for downstream mass
spectrometry analysis. Briefly, three replicates of pSILAC-labeled
protein lysates were separated by SDS-PAGE, the Coomassie G-
250 gel lanes were subsequently in-gel digested with trypsin,
followed by analysis of the tryptic peptides using a nanoLC with an
87-min gradient of increasing acetonitrile from 7 to 40% which
was directly coupled to an LTQ-Orbitrap XL mass spectrometer
operated in data-dependent mode and lock mass option. Raw data
were analyzed using MaxQuant [54], the human IPI database,
and Mascot 2.2. See File S1 for a detailed description.
39- untranslated region (39-UTR) cloning, mutation and
luciferase reporter assay
Validation of miR-targets was performed by cloning complete
39-UTR of predicted genes. For this, PCR products designed to
have restriction sites for XhoI and NotI (for primer sequence please
refer to Table S3) were subcloned into pCR2.1-TOPO (Invitro-
gen) and subsequently cloned into the psiCHECK-2 plasmid from
Promega (Madison, WI, USA). Putative miRNA binding sites were
mutated using the QuikChange Site-Directed Muta-genesis Kit
(Stratagene). Primer sequences designed to generate the mutations
are displayed in Table S3. Insert’s correctness of all constructs was
confirmed by sequencing. Luciferase reporter assays were
performed by cotransfecting HeLa cells with psiCHECK-2
constructs containing wildtype or mutated 39-UTRs and ctrl
miR or miR-133b. Forty-eight h post-transfection, cells were
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Luciferase activity was measured in a Victor Luminometer (Perkin
Elmer, Waltham, MA, USA) using the Dual-Luciferase Reporter
Assay System from Promega. Total Renilla luciferase activity was
calculated by normalizing to firefly luciferase in order to correct
for differences in transfection efficiency.
Statistics
Unless otherwise specified, data shown are representative of at
least three independent experiments. Statistical significance was
calculated by two-tailed Student’s t-test and p,0.05 was
considered significant. Statistical analyses of RT-qPCR data from
primary tissue was performed using PASW statistics 18.0.0 (SPSS
Inc., Chicago, IL, USA), GraphPad version 5.00 (GraphPad
Software Inc. La Jolla, CA, USA) and Medcalc version 11.0
(MedCalc Software, Mariakerke, Belgium). Kolmogorov-Smirnov,
Wilcoxon signed rank test and Spearman correlation were used.
All tests were performed two-tailed and p,0.05 was considered
significant. Receiver operating characteristic (ROC) curves were
calculated and univariate logistic regression was performed to
determine the discriminative power. For survival analyses Kaplan-
Meier approach (log rank test) and Cox proportional hazard
regression were used.
Supporting Information
Figure S1 Kaplan–Meier plot of miR-133b. Ratio of miR-
133b in prostate tumor tissue versus normal adjacent tissue was
dichotomized according to the median expression ratio. Differ-
ences in recurrence-free survival were analyzed by log rank test.
(PDF)
Figure S2 Ability of miR-133b to discriminate prostate
cancer tissue and normal adjacent tissue. ROC analysis
was performed on miR-133b expression. Dotted line indicates an
AUC of 0.5.
(PDF)
Figure S3 miR-133b controls expression of GSTP1 in
PC3 cells. Western blot and densitometric analysis of GSTP1
expression. PC3 cells were transfected with miR-133b alone or
together with ctrl amiR or a specific amiR-133b. After 48 h,
cellular protein lysates were prepared and GSTP1 expression was
assessed by Western blot. GAPDH was used as an internal loading
standard. Ctrl miR-transfected cells were used as a reference for
densitometric quantification of protein band intensity.
(PDF)
Figure S4 miR-133b controls expression of FAIM in PC3
cells. Western blot and densitometric analysis of FAIM
expression. PC3 cells were transfected with miR-133b alone or
together with ctrl amiR or a specific amiR-133b. After 48 h,
cellular protein lysates were prepared and FAIM expression was
assessed by Western blot. b-actin was used as an internal loading
standard. Ctrl miR-transfected cells were used as a reference for
densitometric quantification of protein band intensity.
(PDF)
Figure S5 Western blots of ERK and AKT1 and their
phosphorylated modifications to determine activation
status of these pathways after miR-133b transfection.
HeLa and PC3 cells were transfected with miR-133b or a control
miR (cntrl miR). 48 hours posttransfection whole cell extracts
were prepared and the expression of A) AKT1/p-AKT1 and B)
ERK/p-ERK was assessed using specific antibodies (AKT1,
C67E7; p-AKT, D9E; ERK, 137F5; p-ERK, Y204, all antibodies
available at Cell Signaling, Danvers, MA, USA). Since there is
a big difference in the molecular weight of GAPDH and AKT1/p-
AKT1 they could be probed on the same blot whereas for ERK/
p-ERK and GAPDH different blots had to be used.
(PDF)
Table S1 Antibodies used for Western blot analysis.
(PDF)
Table S2 Primer sequences used for PCR.
(PDF)
Table S3 Primers used for generation of luciferase
reporter constructs
(PDF)
File S1 Detailed description of the pSILAC protocol.
(PDF)
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